• Linkedin
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Gplus
  • Youtube
  • Rss
  • Home
  • Events
  • Careers at CAPTIS
  • Log In / Sign In ▼
    • Log In with LinkedIn
    • Register w/out LinkedIn
    • Login w/out LinkedIn
    • Reset Lost Password
  • 🔒 MEMBER AREA ▼
    • View your profile
    • Edit your profile
    • Log out
       ☎ US Offices 1 (800) 445-1839 Toll Free | Europe/Int'l +41 22 518 2100
CAPTIS Executive Search
  • Home
  • You are a Business
    • Executive Search
    • Our Commitments
    • Other Services
    • Our Locations
    • About Us
    • Key Values
  • You are a Healthcare Executive
    • Dealing with CAPTIS
    • Candidate Contact Form
    • Login with LinkedIn
    • Create an Account
    • Log in (Existing Account)
    • WW Trade Shows
      • Medical & Pharmaceutical
      • Orthopedics
      • Spine
      • Cardiovascular
      • Diagnostics
      • Wound Care
      • Plastic & Aesthetic Surgery
      • Surgery
      • Trauma
      • Pediatric Care
    • Industry News
      • News
      • Wall Street Beat
      • Business/Financial News
      • Clinical Trials
      • Musculoskeletal News Roundup
      • Cardiovascular
      • M&A Activity
      • Food & Drug Administration (FDA)
      • Wound Care
      • Practice Management
  • CAPTIS Magazine
    • Healthcare News
    • @CaptisCorp Twitter Timeline
    • Healthcare Events
    • CAPTIS LinkedIn Timeline
    • Articles ➜
      • Recruiting
      • Personal Development
      • News
  • Make an Inquiry
  • Contact Us
    • General Contact Form
    • Healthcare Executive Contact
    • Apply for a position at CAPTIS
    • Call 1 800 445 1839
      (Cell/Mobile US & Canada Toll Free, or Skype)
    • Call +41 22 518 2100
      (Cell/Mobile Swiss Landline Switchboard, or Skype)
  • Search
  • Menu

Captare. Aestimare. Eligere. Succedere.

CAPTIS – Your Global Healthcare & MedTech Executive Search Provider

You are a Business

You are an Executive

Want to work at CAPTIS

Learn about our services

 

 

Executive Search
Submit an inquiry

GET HEADHUNTED!

Create and/or update

your confidential profile

 

Healthcare Executive General Information
Create an account & Add your profile

Go to our Careers page

 

 

 

 

 

CAPTIS Careers

Recent Healthcare News:

06/17/2019/by CAPTIS

Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria

Sustained efficacy of ULTOMIRIS was observed on the co-primary…
06/17/2019/by CAPTIS

Dr. Reddy’s to sell neurology branded products to Upsher-Smith Laboratories

06/17/2019/by CAPTIS

AstraZeneca’s Lokelma shows significant effect in ESRD trial

06/14/2019/by CAPTIS

IBM, KPMG, Merck and Walmart to assess use of blockchain to protect pharmaceutical product integrity

06/14/2019/by CAPTIS

Corvidia Therapeutics initiates phase 2b dose-finding study for Ziltivekimab

06/13/2019/by CAPTIS

FDA approves Amgen and Allergan’s rastuzumab biosimilar Kanjinti

06/13/2019/by CAPTIS

Pfizer announces results from XELJANZ XR ORAL Shift study

06/13/2019/by CAPTIS

Vernalis, PhoreMost announce drug discovery collaboration for novel oncology target

06/13/2019/by CAPTIS

Dassault Systèmes to buy Medidata Solutions for £4.5bn

06/12/2019/by CAPTIS

FDA extends approval of Merck’s Keytruda in head and neck cancer

06/12/2019/by CAPTIS

Boehringer Ingelheim, University of Dundee extend anti-cancer alliance

This brings together the expertise of Professor Alessio Ciulli,…
06/12/2019/by CAPTIS

Novartis’ Cosentyx achieves primary and secondary endpoints in psoriatic arthritis study

06/12/2019/by CAPTIS

Debiopharm, Ipsen extend strategic Decapeptyl partnership for another 15 years

06/11/2019/by CAPTIS

Genentech secures FDA accelerated approval for Polivy, BR combo for DLBCL

06/11/2019/by CAPTIS

Dr. Reddy’s announces positive topline results from phase 2b study of PPC-06 in moderate to severe plaque psoriasis

06/11/2019/by CAPTIS

Aptar acquires Nanopharm and Gateway Analytical to accelerate customer drug development

06/11/2019/by CAPTIS

Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal

06/10/2019/by CAPTIS

Theramex signs exclusive licensing and supply rights deal with TherapeuticsMD

06/10/2019/by CAPTIS

nference enters into R&D data science partnership with Janssen

06/10/2019/by CAPTIS

ProtoKinetix achieves primary objective safety at midpoint of clinical trial

Go to the Healthcare News

Recent news from your industry: Finance, M&A, Products, Companies and more…

Upcoming Events:

We Suggest:

Acucela gets European orphan designation for emixustat to treat Stargardt disease

0 Comments
/
06/10/2019
In January 2017, Acucela had received orphan drug designation…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-10 00:41:072019-06-10 00:41:08Acucela gets European orphan designation for emixustat to treat Stargardt disease

Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial

0 Comments
/
06/07/2019
The Calquence, obinutuzumab combination registered a statistically-significant…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-07 04:32:552019-06-07 04:32:57Calquence, obinutuzumab combo meets primary endpoint in phase 3 CLL trial

Novartis presents first-of-its-kind histology data with iscalimab

0 Comments
/
06/07/2019
“Extending the life of transplanted kidneys would mean…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-07 00:30:592019-06-07 00:31:01Novartis presents first-of-its-kind histology data with iscalimab

Vertex Pharmaceuticals to buy US firm Exonics Therapeutics

0 Comments
/
06/07/2019
Under the deal, Exonics equity holders will receive $245m (£192m)…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-07 00:01:472019-06-07 00:01:48Vertex Pharmaceuticals to buy US firm Exonics Therapeutics

Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease

0 Comments
/
06/06/2019
The Phase 1 study will evaluate the safety, tolerability, and…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-06 23:01:582019-06-06 23:02:00Goldfinch Bio initiates phase 1 clinical trial of GFB-887 for kidney disease

Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL

0 Comments
/
06/06/2019
The venetoclax, obinutuzumab combination met the primary endpoint…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-06 06:01:362019-06-06 06:01:37Venetoclax, obinutuzumab combo meets objective in phase 3 trial in CLL

CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC

0 Comments
/
06/06/2019
The trial is a multi-center, open-label, and multi-dose Phase…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-06 02:31:112019-06-06 02:31:15CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC

Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD

0 Comments
/
06/06/2019
ADPKD is the most common inherited form of kidney disease affecting…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-06 01:31:562019-06-06 01:31:57Reata Pharmaceuticals gets orphan drug designation for bardoxolone methyl to treat ADPKD

Eli Lilly gets FDA nod for Emgality to treat episodic cluster headache

0 Comments
/
06/06/2019
Emgality, which is an advanced therapeutic approach for the neurologic…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-06 00:02:122019-06-06 00:02:15Eli Lilly gets FDA nod for Emgality to treat episodic cluster headache

EC approves ZYNTEGLO gene therapy for transfusion-dependent β-thalassemia

0 Comments
/
06/04/2019
The approval for ZYNTEGLO is for the treatment of TDT in patients…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-04 18:01:302019-06-04 18:01:31EC approves ZYNTEGLO gene therapy for transfusion-dependent β-thalassemia

FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia

0 Comments
/
06/04/2019
The FDA initially approved Zerbaxa in 2014 to treat complicated…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-04 03:01:132019-06-04 03:01:15FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia

LYNPARZA delivers 72% ORR in phase 3 SOLO3 trial in advanced ovarian cancer

0 Comments
/
06/04/2019
The results were presented at the 55th Annual Meeting of the…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-04 03:01:102019-06-04 03:01:12LYNPARZA delivers 72% ORR in phase 3 SOLO3 trial in advanced ovarian cancer

Novartis’ Kisqali increases OS in HR+/HER2- advanced breast cancer in phase 3 trial

0 Comments
/
06/03/2019
The Kisqali combination therapy, which was evaluated in both…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-03 23:31:092019-06-03 23:31:11Novartis’ Kisqali increases OS in HR+/HER2- advanced breast cancer in phase 3 trial

Kite, Humanigen to evaluate Yescarta, Lenzilumab combo in relapsed/refractory DLBCL

0 Comments
/
06/03/2019
The objective of this study is to determine the effect of lenzilumab…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-03 03:31:292019-06-03 03:31:30Kite, Humanigen to evaluate Yescarta, Lenzilumab combo in relapsed/refractory DLBCL

Imfinzi is only immunotherapy to demonstrate overall survival at three years in unresectable stage III non-small cell lung cancer

0 Comments
/
06/03/2019
These latest results show a durable and sustained OS benefit…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-03 03:02:022019-06-03 03:02:04Imfinzi is only immunotherapy to demonstrate overall survival at three years in unresectable stage III non-small cell lung cancer

Genentech’s Xolair achieves co-primary and key secondary endpoints in chronic rhinosinusitis study

0 Comments
/
06/03/2019
The company has revealed the positive topline data from two phase…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-06-03 00:31:072019-06-03 00:31:09Genentech’s Xolair achieves co-primary and key secondary endpoints in chronic rhinosinusitis study

Vertex to submit VX-445, Tezacaftor and Ivacaftor regimen for global regulatory approvals in cystic fibrosis

0 Comments
/
05/31/2019
Final data announced today from a 24-week Phase 3 study in people…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-31 03:01:092019-05-31 03:01:10Vertex to submit VX-445, Tezacaftor and Ivacaftor regimen for global regulatory approvals in cystic fibrosis

Epizyme submits NDA to US FDA for tazemetostat to treat epithelioid sarcoma

0 Comments
/
05/31/2019
Tazemetostat is an oral, first-in-class, EZH2 inhibitor discovered…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-31 01:01:302019-05-31 01:01:31Epizyme submits NDA to US FDA for tazemetostat to treat epithelioid sarcoma

Lantheus, NanoMab to offer novel biomarker to develop immuno-oncology therapies

0 Comments
/
05/30/2019
As part of strategic collaboration and licence agreement, the…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-30 23:31:492019-05-30 23:31:50Lantheus, NanoMab to offer novel biomarker to develop immuno-oncology therapies

Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists

0 Comments
/
05/30/2019
It will bring together Gubra’s established expertise in…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-05-30 03:01:072019-05-30 03:01:09Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists
PreviousNext

  • Thorough Network

  • Deep Knowledge

  • Comprehensive Process

  • Ethical Approach

  • Confidentiality

  • Assessment Capacity

99%

Percentage of successful project completion

85%

Of placed executives remain with the client company 3 or more years

  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

News from Twitter

Twitter
BIO Intl Convention
BIO Intl Convention
@BIOConvention

Registration in the Grand Hall zipping right along at #BIO2019 this morning! We are looking forward to a great day of Partnering, education and networking. pic.twitter.com/e6Hb…

reply retweet favorite
11:12 am · 06/04/2019 ·
Retweeted by CAPTIS
Twitter
BIO Intl Convention
BIO Intl Convention
@BIOConvention

Good morning, Philadelphia! It's officially day 1 of #BIO2019-- here are today's highlights. View the full schedule of today's events in myBIO: bit.ly/2KfZcWp pic.twitter.com/w6uv…

reply retweet favorite
11:11 am · 06/04/2019 ·
Retweeted by CAPTIS
Twitter
Centinel Spine
Centinel Spine
@CentinelSpine

Congratulations to Rory Sabbatini, prodisc® athlete-ambassador, on his 6th place finish at the @CSChallengeFW. Rory and @BrianGayPGA played the green well this weekend—while educating @PGATOUR fans on spinal surgery with prodisc. bit.ly/2W9cUSb #regainyourlife

reply retweet favorite
9:47 pm · 05/28/2019 ·
Retweeted by CAPTIS
Twitter
TranS1
TranS1
@TranS1

I am lucky to work for a company that gives a person the ability to want to make every day count. TranS1 has given me the ability to stop looking back and remember how to live a life - Get back to living! #tuesdayteammember #T14life #lovewhereyouwork #lovewhatyoudo pic.twitter.com/IiCV…

reply retweet favorite
9:47 pm · 05/28/2019 ·
Retweeted by CAPTIS
Twitter
Quantum Genomics
Quantum Genomics
@QuantumGenomics

Nous profitons de la #JournéeMondialeContreLHypertension pour vous rappeler que notre mission est de développer de nouvelles thérapies innovantes pour les besoins médicaux non satisfaits dans le domaine des maladies cardiovasculaires. #Hypertension #Firibastat #QuantumGenomics pic.twitter.com/bELl…

reply retweet favorite
12:12 pm · 05/18/2019 ·
Retweeted by CAPTIS
Twitter
CAPTIS
CAPTIS
@CaptisCorp

Let's meet at #AAOS2019 in Las Vegas. Feel free to make contact. pic.twitter.com/Cybu…

reply retweet favorite
4:11 pm · 03/14/2019
Twitter
Dr. Alfredo Figueiredo
Dr. Alfredo Figueiredo
@AlfredoFig1

#LowBackPain - a good summary by the European Spine Society @EUROSPINESoc eurospinepatientline… #Orthopaedics #SpineSurgery pic.twitter.com/yo6E…

reply retweet favorite
5:05 am · 02/21/2019 ·
Retweeted by CAPTIS
Twitter
CAPTIS
CAPTIS
@CaptisCorp

Happy President's Day from CAPTIS!

reply retweet favorite
5:06 pm · 02/18/2019
Twitter
Medtronic Spine
Medtronic Spine
@Medtronic_Spine

We are saddened to share the news of the passing of Dr. Yves Cotrel. A pioneer in modern spine surgery, Dr. Cotrel's company Sofamor, was the foundation for what would become Medtronic Spine. Dr. Cotrel's contributions will live on for years to come. Condolences to his family. pic.twitter.com/JJ1Z…

reply retweet favorite
5:27 pm · 02/01/2019 ·
Retweeted by CAPTIS
Twitter
Arab Health
Arab Health
@Arab_Health

The 44th edition of Arab Health is officially now open. #ArabHealth2019 runs until the 31st of January 2019 at the Dubai World Trade Centre and the Conrad Dubai from 10 am to 6 pm. Find out more on our website or download the Arab Health 2019 show app: bit.ly/2n3Z5Q pic.twitter.com/oasI…

reply retweet favorite
5:35 pm · 01/29/2019 ·
Retweeted by CAPTIS
Twitter
Novartis Cancer
Novartis Cancer
@NovartisCancer

Cancer is not a ‘one size fits all,’ nor is the way we treat it. We are working to better understand the different ways a cancer can mutate so we can discover new approaches to treat some of the most difficult-to-treat types of the disease. #ReimagineMedicine #ESMO18 pic.twitter.com/41QL…

reply retweet favorite
6:56 pm · 10/24/2018 ·
Retweeted by CAPTIS
Twitter
Epic CV
Epic CV
@Epic_CV

Read carefully employer's directions on how to apply. #resume #resumetips

reply retweet favorite
7:47 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
World Spine Care
World Spine Care
@WorldSpineCare

Here are 5 Tips to Avoid Back Pain from #WorldSpineDay. #Exercise #Posture #Stress #HealthyEating #Strength pic.twitter.com/AT1D…

reply retweet favorite
7:46 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Neurochecklists
Neurochecklists
@neurochecklists

Large-vessel giant cell arteritis: diagnosis, monitoring and management | Rheumatology | Oxford Academic academic.oup.com/rhe…

reply retweet favorite
7:40 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Stryker Endoscopy
Stryker Endoscopy
@StrykerEndo

Scientists have made an unexpected discovery while investigating the triggering factors of #ColonCancer: Cell stress in combination with an altered microbiota in the colon drives tumor growth. Learn more: ow.ly/JxtK30meLTY pic.twitter.com/U51Q…

reply retweet favorite
7:39 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
Implantech
Implantech
@Implantech

If you are in Dallas attending the AAFPRS 12th International Symposium of Facial Plastic Surgery don’t miss out on this Breakfast Symposium tomorrow morning with Dr. William Binder that is sponsored by Implantech! #implantech #superiorpatientaesthetics #implantechrewards #aafprs pic.twitter.com/HCzK…

reply retweet favorite
7:38 am · 10/16/2018 ·
Retweeted by CAPTIS
Twitter
American College of Cardiology
American College of Cardiology
@ACCinTouch

Less than one month left to submit your science for #ACC19! Abstract & case submissions are due Oct. 16. Learn more: ow.ly/4nyf30lYZxh pic.twitter.com/Mnwv…

reply retweet favorite
4:46 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Novartis Cancer
Novartis Cancer
@NovartisCancer

With #CARTcell therapy, an inactive virus programs T cells with new genetic information to help recognize specific antigens found on normal cells and certain blood cancer cells. As the CAR-T cells multiply, new copies also gain this ability. #CARTCellStory pic.twitter.com/Xuoh…

reply retweet favorite
4:42 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Integra LifeSciences
Integra LifeSciences
@integra_life

Make plans to visit the Integra LifeSciences Booth# 919 during Plastic Surgery The Meeting September 28th - October 1st. #Integra_LifeSciences #DurableIsBeautiful #PSTM18 #ASPS #PlasticSurgery pic.twitter.com/8QGv…

reply retweet favorite
4:42 pm · 09/26/2018 ·
Retweeted by CAPTIS
Twitter
Fundamental Surgery
Fundamental Surgery
@FundamentalSurg

We are live at #NASS2018 stand 2649. Get hands-on with the world's leading surgical #simulator in #VR with #haptics and experience the future of surgical training. #wearefundamental fundamentalsurgery.c… pic.twitter.com/NgzA…

reply retweet favorite
4:41 pm · 09/26/2018 ·
Retweeted by CAPTIS
Follow @CaptisCorp

Follow CAPTIS



CAPTIS
Followon TwitterSubscribeto RSS Feed

We Recommend

Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News

CAPTIS Newsletter

Call CAPTIS

United States Offices
1 (800) 445-1839

(United States & Canada Toll Free)

Europe & International
+41 22 518 2100

© CAPTIS - Executive Search - 2017 - copyright@captis.com
  • Linkedin
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Gplus
  • Youtube
  • Rss
  • Events
  • For Healthcare Executives
  • Legal & Privacy Notes, GDPR & Cookies Policy
  • Client Area
X
Thank you for visiting our new website! Help us improve, let us know your feedback (Anonymous 2 min survey)
Survey
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK, got itCookies Policy
Scroll to top